Pallavi Sachdev
Executive Director & Head of Translational Medicine & Clinical Research Eisai
Seminars
Highlighted by the recent approval of the first in vivo blood test for Alzheimer’s Disease, advancements in new technologies to measure p-tau217 are at an all-time-high. Join this session for an inside look on how p-tau217 is setting the gold standard in AD diagnostics, exploring its scientific evolution, clinical impact, and regulatory breakthrough, offering a model for future biomarker development.
In this session:
- Explore the progression of phosphorylated Tau from cerebrospinal fluid (CSF) assays to more scalable and accessible blood-based tests
- Discuss the role of p-tau217 in enriching clinical trial populations and enabling more accurate disease staging and monitoring
- Examine current limitations, including questions around specificity, diagnostic breadth, and standardization
- Assess regulatory interest in p-tau217 as a potential surrogate endpoint and what is needed to achieve that designation
- Review lessons from recent clinical trials and biomarker validation efforts
- Identify ongoing research gaps and collaborative opportunities to accelerate adoption and approval
Exploring how integrative multi-omics approaches are transforming our ability to decode disease complexity, particularly in heterogeneous neurological disorders like Alzheimer’s, Parkinson’s, MS, and ALS. Gain insight into how combining omics layers can improve biomarker discovery, support precision medicine, and drive better patient stratification.
- The limitations of relying on single-omic data in complex, multi-pathway diseases
- Overview of multi-omics: Combining layers to contextualise molecular interactions
- How integrated data enhances the resolution and specificity of biomarker discovery
- The Omics Spectrum: Genomics, transcriptomics, proteomics, epigenomics, lipidomics & metabolomics
- Discussion of emerging omics layers: Glycomics, single-cell omics and secretomics
Exploring the evolving role of alpha-synuclein in Parkinson’s and related disorders, focusing on both its promise and its limitations. Delve into the challenges of using alpha-synuclein for patient stratification and monitoring in clinical trials, review cutting-edge blood-based and seed amplification assay technologies that aim to reduce reliance on imaging, and unpack the complex biology of protein aggregates.
In this session:
- Examine the role of alpha-synuclein in Parkinson’s and related synucleinopathies, and explore the key challenges limiting its use in clinical trial stratification and disease monitoring
- Evaluate emerging seed amplification assays and blood-based detection methods aiming to reduce reliance on invasive CSF collection or expensive imaging techniques for diagnosis and staging
- Discuss the biological complexity of protein aggregates and whether understanding their behaviour can provide insight beyond mere disease correlation – single particle proteomics
